Combined Influence of Genetic Polymorphism and DNA Methylation on ABCB1 Expression and Function in Healthy Chinese Males

[1]  Y. Li,et al.  Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects. , 2015, British journal of clinical pharmacology.

[2]  Paolo Garagnani,et al.  The epigenetic side of human adaptation: hypotheses, evidences and theories , 2015, Annals of human biology.

[3]  L. Davidson,et al.  Noninvasive molecular fingerprinting of host–microbiome interactions in neonates , 2014, FEBS letters.

[4]  M. Gottesman,et al.  MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. , 2014, Cancer research.

[5]  A. Nader,et al.  Suitability of digoxin as a P‐glycoprotein probe: Implications of other transporters on sensitivity and specificity , 2014, Journal of clinical pharmacology.

[6]  T. Marquès-Bonet,et al.  DNA methylation contributes to natural human variation , 2013, Genome research.

[7]  H. Gréen,et al.  ABCB1 gene polymorphisms are associated with suicide in forensic autopsies , 2013, Pharmacogenetics and genomics.

[8]  K. Oka,et al.  Decitabine, a DNA methyltransferase inhibitor, reduces P-glycoprotein mRNA and protein expressions and increases drug sensitivity in drug-resistant MOLT4 and Jurkat cell lines. , 2012, Anticancer research.

[9]  Jingbo Wang,et al.  An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics , 2011, The Pharmacogenomics Journal.

[10]  I. Ieiri,et al.  Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: relationship to epigenetic variations in the 5'-upstream regulatory region. , 2011, Journal of pharmaceutical sciences.

[11]  R. Altman,et al.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). , 2011, Pharmacogenetics and genomics.

[12]  Hein Putter,et al.  Variation, patterns, and temporal stability of DNA methylation: considerations for epigenetic epidemiology , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  C. Sapienza,et al.  Inter- and Intra-Individual Variation in Allele-Specific DNA Methylation and Gene Expression in Children Conceived using Assisted Reproductive Technology , 2010, PLoS genetics.

[14]  Joseph D. Ma,et al.  Evaluation of In Vivo P-Glycoprotein Phenotyping Probes , 2010, Clinical pharmacokinetics.

[15]  T. Aas,et al.  DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response , 2010, Molecular Cancer.

[16]  Achim Tresch,et al.  Spatial, temporal and interindividual epigenetic variation of functionally important DNA methylation patterns , 2010, Nucleic acids research.

[17]  J. Sprowl,et al.  The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance , 2010, The Pharmacogenomics Journal.

[18]  Gang-yi Liu,et al.  Therapeutic monitoring of serum digoxin for patients with heart failure using a rapid LC-MS/MS method. , 2010, Clinical biochemistry.

[19]  Rong Liu,et al.  Correlation between MDR1 methylation status in the promoter region and MDR1 genetic polymorphism in 194 healthy Chinese Han subjects. , 2008, Pharmacogenomics.

[20]  Huande Li,et al.  Impact of MDR1 Haplotypes Derived from C1236T, G2677T/A and C3435T on the Pharmacokinetics of Single-Dose Oral Digoxin in Healthy Chinese Volunteers , 2008, Pharmacology.

[21]  S. Yagi,et al.  Epigenetics: the DNA methylation profile of tissue-dependent and differentially methylated regions in cells. , 2008, Placenta.

[22]  M. Pirmohamed,et al.  ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research , 2007, The Pharmacogenomics Journal.

[23]  Michel Eichelbaum,et al.  Interindividual variability of canalicular ATP‐binding‐cassette (ABC)–transporter expression in human liver , 2006, Hepatology.

[24]  B. Meibohm,et al.  G2677T and C3435T Genotype and Haplotype Are Associated With Hepatic ABCB1 (MDR1) Expression , 2006, Journal of clinical pharmacology.

[25]  J. Zalcberg,et al.  Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs , 2005, Oncogene.

[26]  Andrew D. Johnson,et al.  Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability , 2005, Pharmacogenetics and genomics.

[27]  A. M. George,et al.  The ABC transporter structure and mechanism: perspectives on recent research , 2004, Cellular and Molecular Life Sciences CMLS.

[28]  R. Ho,et al.  (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function , 2004 .

[29]  K. Budde,et al.  MDR1 Haplotypes Do Not Affect the Steady‐State Pharmacokinetics of Cyclosporine in Renal Transplant Patients , 2003, Journal of clinical pharmacology.

[30]  Werner Siegmund,et al.  The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol , 2002, Clinical pharmacology and therapeutics.

[31]  G. Kessie,et al.  Markers of Inflammation and Lineage on Exfoliated Colonic Cells In Pediatric Inflammatory Bowel Disease. , 2011, Journal of gastrointestinal & digestive system.

[32]  H. Glaeser.  Importance of P-glycoprotein for drug-drug interactions. , 2011, Handbook of experimental pharmacology.

[33]  F. Wang,et al.  Up-regulation of ABCB1/P-glycoprotein by escaping promoter hypermethylation indicates poor prognosis in hematologic malignancy patients with and without bone marrow transplantation. , 2011, Leukemia research.

[34]  R. Ho,et al.  The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. , 2004, Current drug metabolism.